Urology Research & Practice
Original Article

Prognostic value of carbonic anhydrase IX and HIF-1α in renal cell carcinoma

1.

İstanbul Göztepe Eğitim ve Araştırma Hastanesi, 1. Üroloji Kliniği, İstanbul

2.

Department of Urology, İstanbul Medeniyet University Goztepe Training and Research Hospital, İstanbul

3.

Department of Pathology, İstanbul Medeniyet University Goztepe Training and Research Hospital, İstanbul

4.

Department of Urology, Faculty of Medicine, İstanbul Medeniyet University, İstanbul, Turkey

Urol Res Pract 2012; 38: 1-7
DOI: 10.5152/tud.2012.001
Read: 1389 Downloads: 885 Published: 25 July 2019

Abstract

Objective: In this study, we evaluated the prognostic value of carbonic anhydrase IX (CA9) and HIF-1α and their relations with anatomic, histopathologic and clinic prognostic factors.

 

Materials and Methods: Immunohistochemical analysis was performed on paraffin-embedded specimens from 39 patients treated with a nephrectomy for renal cell carcinoma. The immunoreactivity levels of CA9 and HIF-1α were classified into four groups: 0%, 1-25%, 26-50%, >50% for CA9; and ≤1-10%, 11-50%, 51-80%, >80% for HIF-1α. The CA9 and HIF-1α stains were compared with the patient’s age, sex, tumor volume, recurrence status, T stage and Fuhrman grade. 

 

Results: The age distribution of all patients with clear cell renal cell carcinoma (RCC) was as follows: 23 (59%) were older than 50, and 16 (41%) were younger. Twenty-eight patients (71.8%) were male, and 11 (28.2%) were female. Among these patients, 34 (87.2%) survived, and 5 (12.8%) died because of RCC. Seven (17.9%) patients had a recurrence after undergoing a nephrectomy. Twenty-four (61.5%) patients were classified as stage T1 and 15 (38.2%) as stage T2. Thirty-three (84.6%) patients were classified as Fuhrman grade 2 and six (15.4%) patients as Fuhrman grade 3. Although there were different degrees of staining, immunohistochemical staining was positive in all pathological samples for either CA9 or HIF-1α (7 1-25%, 15 26-50%, 17 >%50 for CA9; 11 <10%, 10 10-50%, 14 50-80%, 4 >80% for HIF-1α). Among the CA9 immunoreactive-positive patients, the number of male patients was statistically higher in the 1-25% group than the 26-50% and >50% groups (p=0.019). Among HIF-1α immunoreactive-positive patients, the ≤%10 group had a statistically lower number of tumors sized >4 cm than the other groups (p=0.01). 

 

Conclusions: We noted that there was no relationship between CA9 and HIF-1α expression with other prognostic clinicopathologic features.

Files
EISSN 2980-1478